News Release
Mallinckrodt plc Celebrates 20 Years of Successful Operations in Ireland
Newly independent global specialty pharmaceuticals company marks
spin-off and anniversary
DUBLIN--(BUSINESS WIRE)--Nov. 6, 2013--
Today, Mallinckrodt plc (NYSE: MNK) celebrates its official launch as a
public limited company (plc) in Ireland, as well as the 20th anniversary
of the opening of its Dublin manufacturing plant at its facilities in
Damastown Industrial Park. The event – whose honored guests include Leo
Varadkar, M.D., T.D., Minister for Transport, Tourism and Sport for the
Government of Ireland, and Mark Trudeau, President and CEO of
Mallinckrodt – celebrates the global specialty pharmaceuticals company
strong Irish heritage and its commitment to driving future growth and
manufacturing excellence.
Over the span of two decades of operations in Ireland, Mallinckrodt has
employed hundreds of local citizens and made investments in the
community at large. The company’s manufacturing facility produces a
major bulk active pharmaceutical ingredient for contrast media,
manufactures clinical-trial material and performs drug product release
for imaging and pharmaceutical products for markets in Europe.
Mallinckrodt has also been an active supporter of JobBridge, the
government-sponsored internship placement program, for the past 18
months. Through JobBridge, these interns have developed and enhanced
their skills at Mallinckrodt’s state-of-the-art facilities.
“We are incredibly proud of our long-standing presence in Ireland, the
investment we have made in the local community and our talented staff
who embody quality, integrity and service every day,” said Mr. Trudeau.
“Our Dublin plant is one of the top-performing sites within
Mallinckrodt, and a key growth driver as we continue to unlock our
potential as a leading global specialty pharmaceuticals company.”
To date, Mallinckrodt has made a capital investment of more than €100
million, and plans to grow in the years ahead. Building on its
commitment to deliver the highest level of quality products and services
reliably and safely, the company is developing the Dublin plant as a
knowledge centre of excellence within Mallinckrodt for continuous
improvement processes.
“The healthcare industry offers continued potential to create jobs and
grow our economy, as well as contribute to the health and well-being of
our citizens,” said Minister Varadkar. “Mallinckrodt’s investment in and
partnership with the Irish community is a valued example of this. We
look forward to 20 more years together, and beyond.”
In Dublin, Mallinckrodt employs more than 100 individuals in its
Principle Executive Office and Manufacturing Facility. The
82,000-square-foot state-of-the-art, facility has produced ioversol, a
bulk active pharmaceutical ingredient for contrast media,
since 1993.
Mallinckrodt became a plc in January 2013, to hold the pharmaceuticals
business of Covidien, which was spun off on June 28, 2013.
ABOUT MALLINCKRODT:
Mallinckrodt is a global specialty pharmaceuticals business that
develops, manufactures, markets and distributes specialty pharmaceutical
products and medical imaging agents. The company’s Specialty
Pharmaceuticals segment includes branded and generic drugs, and the
Global Medical Imaging segment includes contrast media and nuclear
imaging agents. Mallinckrodt has approximately 5,500 employees worldwide
with direct sales in roughly 70 countries. The company’s 2012 revenue
totaled $2.1 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Source: Mallinckrodt plc
Mallinckrodt plc
Lynn Phillips, 314-654-3263
Manager, Media
Relations
lynn.phillips@mallinckrodt.com
or
Meredith
Fischer, 314-654-3318
Senior Vice President, Communications
meredith.fischer@mallinckrodt.com
or
John
Moten, 314-654-6650
Vice President, Investor Relations
john.moten@mallinckrodt.com